Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer: A more reliable predictor of tumor stage than microvessel density or serum vascular endothelial growth factor

Applied Immunohistochemistry and Molecular Morphology

Volumn 8, Issue 2, 2000, Pages 104-109

  Callagy, G ^b   Dimitriadis, E ^b   Harmey, J ^b   Bouchier Hayes, D ^b   Leader, M ^b   Kay, E ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b NONE

Author keywords

Angiogenesis; Breast cancer; Microvessel density; Tumor stage; Vascular endothelial growth factor

Indexed keywords

CD34 ANTIGEN; TUMOR MARKER; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; MICROCIRCULATION; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033866438     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-200006000-00004     Document Type: Article

References (43)

1. Weidner N, Folkman J. Tumor vascularity as a prognostic factor in cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: Lippincott-Raven, 1996: 167-90.
2. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast cancer. N Engl J Med 1991;324:1-8.
3. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992;23:755-61.
4. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed platelet/ endothelial cell adhesion molecule antibodies, as an indicator of node metastasis and survival in breast cancer. Lancet 1992;340: 1120-4.
5. Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast cancer. Int J Cancer 1993;55;371-4.
6. Jacquemier JD, Penault-Llorca FM, Bertucci F, et al. Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis. J Pathol 1998;184:130-5.
7. Hall NR, Fish DE, Hunt N, Goulding RD, Guillou PJ, Monson JR. Is the relationship between angiogenesis and metastasis in breast cancer real? Surg Oncol 1991;1:223-9.
8. Goulding H, Abdul Rashid N, Robertson JF, Bell JA, Elston CW, Blamey RW, Ellis IO. Assessment of angiogenesis in human breast carcinoma. Hum Pathol 1995;26:1196-200.
9. Costello P, McCann A, Carney DN, Dervan PA. Prognostic significance of microvessel density in lymph node negative breast carcinoma. Hum Pathol 1995;26:1181-4.
10. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol 1998;84:119-22.
11. Van der Laak JAWM, Westphal JR, Schalkwijk LJM, Pahlplatz MMM, Ruiter DJ, De Waal RMW, De Wilde PCM. An improved procedure to quantify tumour vascularity using true colour image analysis. Comparison with the manual hot-spot procedure in a human melanoma xenograft model. J Pathol 1998;184:136-43.
12. Barbareschi M, Weidner N, Gasparini G, et al. Microvessel density quantification in breast carcinomas: assessment by light microscopy vs. a computer-aided image analysis system. Appl Immunohistochem 1995;3:75-84.
13. Weidner N. Measuring intratumoral microvessel density. In: Maragoudakis M, editor. Angiogenesis: models, modulators and clinical applications. New York: Plenum Press, 1998:61-74.
14. Weidner N. Tumor vascularity: what does it tell us about the growth and spread of cancer? In: Maragoudakis M, editor. Angiogenesis: models, modulators and clinical applications. New York: Plenum Press, 1998;389-406.
15. Schor AM, Pendleton N, Pazouki S, et al. Assessment of vascularity in histological sections: effects of methodology and value as an index of angiogenesis in breast tumours. Histochem J 1998;30: 849-56.
16. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, Bundred N. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumour prognosis. Cancer Res 1999;59:856-61.
17. Kato T, Kimura T, Ishii N, et al. The methodology of quantitation of microvessel density and prognostic value of neovascularization associated with long-term survival in Japanese patients with breast cancer. Breast Cancer Res Treat 1999;53:19-31.
18. Hansen S, Grabau DA, Rose C, Bak M, Sorensen FB. Angiogenesis in breast cancer: a comparative study of the observer variability of methods for determining microvessel density. Lab Invest 1998;78:1563-73.
19. Axelsson K, Ljung B-ME, Moore DH II, et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995;87:997-1008.
20. Morphopoulos G, Pearson M, Ryden WJD, Howell A, Harris M. Tumour angiogenesis as a prognostic marker in infiltrating lobular carcinoma of the breast. J Pathol 1996;180:44-9.
21. Fox SB, Leek RD, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, chalkley count, and computer image analysis. J Pathol 1995;177:275-83.
22. Uchida S, Shimada Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, Ishigami S, Imamura M. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 1998;77:1704-9.
23. Shibusa T, Shijubo N, Abe S. Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res 1998;4:1483-7.
24. Amaya H, Tanigawa N, Lu C, Matsumura M, Shimomatsuya T, Horiuchi T, Muraoka R. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett 1997; 119:227-35.
25. Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, Hellman S. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 1996;88:1764-9.
26. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor in node-negative breast carcinoma. J Natl Cancer Inst 1997;89:139-47.
27. Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995;36:193-204.
28. Obermair A, Kucera E, Mayerhofer K, et al. Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease free survival. Int J Cancer 1997;74:455-8.
29. Relf M, LeJeune S, Scott PA, et al. Expression of angiogenic factors vascular endothelial growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet derived growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-9.
30. de Jong J, van Diest PJ, van der Valk P, Baak JPA. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: correlations with proliferation and angiogenesis. J Pathol 1998;184:53-7.
31. Lee AH, Dublin EA, Bobrow LG, Poulsom R. Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis. J Pathol 1998;185:394-401.
32. Allred DC, Clark GM, Elledge SA, Fuqua GM, Brown RW, Chamness GC, Kent Osborne C, McGuire WL. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85: 200-6.
33. Thompson WD, Li WW, Maragoudakis M. The clinical manipulation of angiogenesis: pathology, side-effects, surprises, and opportunities with novel human therapies. J Pathol 1999;187:503-10.
34. Charpin C, Devictor B, Bergeret D, et al. CD31 quantitative immunocytochemical assays in breast carcinomas: correlation with current prognostic factors. Am J Clin Pathol 1995;103:443-8.
35. Heymans O, Blacher S, Brouers F, Pierard GE. Fractal quantification of the microvasculature heterogeneity in cutaneous melanoma. Dermatology 1999;198212-7.
36. Simpson JF, Ahn C, Battifora H, Esteban JM. Endothelial area as a prognostic indicator for invasive breast carcinoma. Cancer 1996; 77:2077-85.
37. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13:9-22.
38. Martin L, Holcombe C, Green B, Leinster SJ, Winstanley J. Is a histological section representative of whole tumour vascularity in breast cancer? Br J Cancer 1997;76:40-3.
39. Harvey J, Clark GM, Kent Osborne C, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine chemotherapy in breast cancer. J Clin Oncol 1999;17:1474-81.
40. Martin L, Green B, Renshaw C, Lowe D, Rudland P, Leinster SJ, Winstanley J. Examining the technique of angiogenesis assessment in invasive breast cancer. Br J Cancer 1997;76:1046-54.
41. Siitonen SM, Haapasalo HK, Rantala IS, Helin HJ, Isola JJ. Comparison of different immunohistochemical methods in the assessment of angiogenesis: lack of prognostic value in a group of 77 selected node-negative breast carcinomas. Mod Pathol 1995;8: 745-52.
42. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and non-malignant disease. Cancer 1999;85:178-87.
43. Turley H, Scott PA, Watts VM, Bicknell R, Harris AL, Gatter KC. Expression of VEGF in routinely fixed material using a new monoclonal antibody. J Pathol 1998;186:313-8.